An Open Label Study to Evaluate G17DT Compared to Gemcitabine

Inclusion Criteria: * A diagnosis of pancreatic adenocarcinoma, confirmed by histology or cytology, in patients not suitable for pancreatic tumor resection with curative intent. * A diagnosis of recurrent pancreatic adenocarcinoma (previously confirmed by histology or cytology) in patients who have had a primary tumor resection. * Male or female patients over 18 years of age. * Laboratory values within the following ranges at screening: Serum creatinine \< 1.25 times upper limit of normal (ULN) Haemoglobin \> 9.5 g/dL White blood cell (WBC) count \> 3.5 x 109/L Platelets \> 100 x 109/L Total bilirubin \< 2.0 times ULN Aspartate transaminase (AST, SGOT) \< 3 times ULN * A life expectancy of at least 2 months. * A negative pregnancy test at the screening visit (females of childbearing potential only). * Signed written informed consent. Exclusion Criteria: * History of other malignant disease (except basal cell carcinoma or in situ carcinoma of the uterine cervix). * Previous cytotoxic chemotherapy (including gemcitabine). * Previous radiotherapy within 30 days of baseline. * Use of systemic (oral or injected) immunosuppressants, including corticosteroids, within 30 days prior to the baseline visit. Inhaled corticosteroids for chronic obstructive pulmonary disease or asthma were permitted. * Females of child bearing potential who are pregnant, lactating, or who are planning to become pregnant during the period of the study. * Participation in another study involving an investigational drug within 90 days of baseline.